Related Experiment Video
Updated: May 21, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Prognostic Factor and Serum Biomarker Changes in Non-Surgical Hepatocellular Carcinoma Patients Treated with
B I Carr1, H G Gozukara Bag2, R Kutlu3
1Liver Transplant Institute, Inonu University Faculty of Medicine, 44280, Malatya, Turkey.
Background:
1.1:Transarterial radioembolization (TARE) with 90Y is a primary therapy for hepatocellular carcinoma (HCC), including patients with portal vein thrombosis (PVT). Patient survival subgroups post TARE have not been clearly defined.
Aims:
1.2.To identify prognostic factors in patients treated with TARE.
Methods:
1.3.Non-surgical HCC patients (n=116) were treated with TARE and prospectively followed for survival and changes in blood parameters relating to inflammation and tumor indices.
Results:
1.4.Baseline parameters with the highest hazard ratios (HR>2) for survival were C-reactive protein, alpha-fetoprotein (AFP), maximum tumor diameter (MTD) and PVT. A 2-parameter prognostic model was developed, consisting of serum AFP and C-reactive protein, which was especially significant in patients with PVT. Temporal changes post TARE in ALBI and serum gamma glutamyl transferase (GGT) levels occurred in patients with both high and low serum AFP. A network phenotyping strategy (NPS) showed that patient phenotypes also change after TARE. Post TARE reduction in AFP or GGT or increase in albumin levels were associated with improved survival.
Conclusions:
1.5.Changes in serum CRP, AFP, GGT, albumin, ALBI, and NPS phenotype occurred early after TARE. Changes in AFP, GGT and albumin related to survival and may be useful in selecting patients for additional treatment.
